Arkuda Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Arsenal Yards Blvd Ste 220, Watertow...Phone Number
(617) 579-1306Website
www.arkudatx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Arkuda Therapeutics
Arkuda Therapeutics is a biotechnology company applying new insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda's lead program aims to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. Beyond progranulin, Arkuda's compounds enhance the activity of several other key lysosomal enzymes, including beta-glucocerebrosidase (GCase), and the company is further exploring the therapeutic potential of its molecules in genetically-defined Parkinson's disease and other neurodegenerative diseases. Arkuda is backed by leading life science investors including Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and Mission BioCapital.Explore more
Arkuda Therapeutics Org Chart
JB
Vice President, Neurobiology
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arkuda Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Arkuda Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Arkuda Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Arkuda Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Arkuda Therapeutics is spiking on competitors!
Check if Arkuda Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Arkuda Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Arkuda Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Arkuda Therapeutics
Recommended Actions
Find VP level buyers at Arkuda Therapeutics
Find 2 more new buyers
Compare Similar Companies to Arkuda Therapeutics
Compare insights from companies similar to Arkuda Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arkuda Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arkuda Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arkuda Therapeutics.
Arkuda Therapeutics financials insights
Gather financial insights about Arkuda Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$44M
2022
Series B
$64M
Arkuda Therapeutics Tech Stack
A closer look at the technologies used by Arkuda Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Board of Directors
Promotion
Executive Move
New Hire
Executive Move
Arkuda Therapeutics News & Media
Arkuda Therapeutics Announces Option and Asset Purchase Agreement
- Arkuda to grant Janssen option to acquire Arkuda's portfolio of lysosomal function enhancers in exchange for upfront option payment and opportunity for additional milestone payments WATERTOWN, Mass., Feb. 7, 2024 /PRNewswire/ -- Arkuda Therapeutics, a biotechnology company applying...Arkuda Therapeutics to Present Update on ARKD-104, its First-in-Class Oral Development Candidate for the Treatment of Frontotemporal Dementia and other Neurodegenerative Disorders at the Alzheimer's Association International Conference 2023
- Study demonstrates ARKD-104 has excellent CNS drug-like properties, increases PGRN in the CNS of non-human primates and increases important cofactors of lysosomal enzymes important to neuronal health - ARKD-104 expected to enter clinical trials for Frontotemporal Dementia in H1 2024...Arkuda Therapeutics Strengthens Management Team to Support Ongoing Discovery and Translation to the Clinic
Duane Burnett, PhD, appointed Chief Technology Officer, Raymond Hurst, PhD, promoted to Senior Vice President, Head of Discovery Irena Webster, MPH, MA, joins as VP, Program Strategy and Development Operations, bringing 20 years of experience in clinical development operations Lead...Arkuda Therapeutics Raises $64 Million Series B Financing to Advance Pipeline of Programs Targeting Lysosomal Biology to Treat Neurodegenerative Diseases
WATERTOWN, Mass., Feb. 10, 2022 /PRNewswire/ -- Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal and microglial biology to develop medicines to change the trajectory of neurodegenerative disease, today announced the completion of a $64...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arkuda Therapeutics
Sign Up For FreeTo access detailed company insights
Arkuda Therapeutics is a biotechnology company applying new insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda's lead program aims to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtyp... Read More
